Last checked at 3 Apr 2023 07:01
MyHealthChecked PLC
("MyHealthChecked" or the "Company")
Proposed Share Consolidation and Notice of AGM
MyHealthChecked PLC (AIM: MHC), the consumer home-testing healthcare company, announces that it will today post a circular to shareholders detailing the Board's proposal to consolidate the Company's share capital with the aim of improving the marketability of the Ordinary Shares. The Circular will also contain the Notice of the Annual General Meeting to be held on 11 May 2023.
A copy of the Circular and Notice of the Annual General Meeting will be available on the Company's website: www.investors.myhealthcheckedplc.com later today. Extracts from the Circular are set out below:
EXPECTED TIMETABLE OF PRINCIPAL EVENTS
| 2023 | ||
Posting of the Circular and the form of proxy | 3 April | ||
Latest time and date for receipt of forms of proxy for the Annual General Meeting
| 11.00 a.m. on 9 May
| ||
Annual General Meeting | 11.00 a.m. on 11 May | ||
Announcement of the result of the Annual General Meeting | 11 May | ||
Record Date in respect of the Share Consolidation and final date for trading in Existing Ordinary Shares | 6.00 p.m. on 11 May | ||
Admission expected to become effective and dealings expected to commence in the New Ordinary Shares on AIM | 8.00 a.m. on 12 May | ||
CREST accounts expected to be credited in respect of New Ordinary Shares in uncertificated form | 12 May | ||
Expected date by which certificates in respect of New Ordinary Shares are to be despatched to certificated Shareholders | By the week commencing on 29 May | ||
DEFINITIONS
The following definitions apply throughout this document, unless the context requires otherwise.
"Admission" | the admission of the New Ordinary Shares to trading on AIM in accordance with Rule 6 of the AIM Rules; |
"Annual General Meeting" or "AGM" | the Annual General Meeting of Shareholders to be held at 11.00 a.m. on 11 May 2023 and any adjournment thereof, to consider and, if thought fit, pass the Resolutions, notice of which is set out at the end of this document |
"AIM" | the market of that name operated by London Stock Exchange plc |
"AIM Rules" | the AIM Rules for Companies whose securities are traded on AIM, as published by the London Stock Exchange from time to time |
"Articles" | the Company's articles of association |
"Board" or "Directors" | the directors of the Company at the date of this Document, whose names are set out on page 6 of this Document |
"Circular" or "Document" | this document dated 3 April 2023 |
"Company" | MyHealthChecked PLC, a company registered in England and Wales with registered number 06573154 |
''CREST'' | the computerised settlement system to facilitate transfer of title to or interests in securities in uncertificated form operated by Euroclear UK & International Limited; |
"Existing Ordinary Shares" | the 780,088,967 ordinary shares of 0.1p each in the capital of the Company in issue at the date of this document, which are admitted to trading on AIM |
"form of proxy" | the form of proxy accompanying this Document (or otherwise available) for use at the Annual General Meeting |
"London Stock Exchange" | London Stock Exchange plc |
"New Ordinary Shares" | the Ordinary Shares of 1.5p each in the capital of the Company arising on the completion of the Share Consolidation |
"Ordinary Shares" | ordinary shares of 0.1p (or, following the Share Consolidation, 1.5p) each in the capital of the Company |
"Record Date" | 6.00 p.m. on 11 May 2023 (or such other time and date as determined by the Directors) |
"Resolutions" | the resolutions set out in the notice of Annual General Meeting |
"Share Consolidation" | the proposed consolidation of the Company's ordinary share capital pursuant to which every 15 Existing Ordinary Shares are consolidated into 1 New Ordinary Share |
"Shareholders" | holders of Ordinary Shares in the Company from time to time |
"Sterling" or "£" | the lawful currency of the UK |
"UK" or "United Kingdom" | the United Kingdom of Great Britain and Northern Ireland
|
"US" or "United States" | the United States of America, its territories and possessions, any states of the United States of America and the District of Columbia and all other areas subject to its jurisdiction. |
STATISTICS
Number of Existing Ordinary Shares Number of Ordinary Shares in issue as at the Record Date | 780,088,967 780,088,980 | |
Conversion ratio of Existing Ordinary Shares to New Ordinary Shares | 15 : 1 |
|
Nominal value of an Ordinary Share following the Share Consolidation | 1.5p |
|
Number of Ordinary Shares in issue immediately following the Share Consolidation | 52,005,932 |
|
New ISIN Code following the Share Consolidation |
GB00BN7K5L93 |
|
New SEDOL Code following the Share Consolidation | BN7K5L9 |
|
TIDM | MHC |
|
LEI | 213800RBHY6LZDG13168 |
|
| ||
1. Introduction
I am writing to you to set out the details of your Board's proposal to consolidate the Company's share capital with the aim of improving the marketability of the Ordinary Shares.
In addition, I am pleased to inform you that this year's annual general meeting will be held on 11 May 2023 at 11.00 a.m. in the Malt Room at The Maltings, East Tyndall Street, Cardiff, CF24 5EA.
The purpose of this document is to provide you with details of the Share Consolidation and the Resolutions to be proposed to Shareholders at the forthcoming Annual General Meeting. The formal Notice of Annual General Meeting is set out at the end of this document (together with a set of explanatory notes) and a form of proxy is also enclosed for you to complete, sign and return.
2. Background to and reasons for the Share Consolidation
As at the date of this document, the Company has 780,088,967 Ordinary Shares in issue, with a closing mid-market price of 1.05 pence per Existing Ordinary Share (as at 31 March 2023, being the latest practicable Business Day prior to the date of this document). The Board believes that the Share Consolidation will improve the marketability of the Ordinary Shares by way of a higher share price and hopes to reduce volatility in the Company's share price by narrowing the spread of its bid and offer price.
It is therefore proposed that the existing ordinary shares of 0.1 pence each are consolidated on a 15 for 1 basis, such that every 15 Existing Ordinary Shares are consolidated into 1 ordinary share of 1.5p pence in nominal value. It is intended that 13 new Ordinary Shares will be allotted to the Company's registrars, Neville Registrars Limited, following the AGM so that the total number of existing Ordinary Shares is exactly divisible by 15 for the Share Consolidation. Assuming a share capital of 780,088,980 Existing Ordinary Shares immediately prior to the Record Date, following completion of the Share Consolidation, the Company will have 52,005,932 New Ordinary Shares in issue.
Application will be made in accordance with the AIM Rules for the New Ordinary Shares arising from the Share Consolidation to be admitted to trading on AIM, subject to Shareholders passing Resolutions 6 and 7 at the Annual General Meeting. It is expected that if such Resolutions are passed, Admission in respect of such New Ordinary Shares will become effective and that dealings in those New Ordinary Shares will commence on 12 May 2023.
No Shareholder will be entitled to a fraction of a New Ordinary Share. Instead, their entitlement will be rounded down to the nearest whole number of New Ordinary Shares. Remaining fractional entitlements to New Ordinary Shares will be aggregated and sold on behalf, and for the benefit of, the Company. If a Shareholder holds fewer than 15 Existing Ordinary Shares at the Record Date, then the rounding down process will result in that Shareholder being entitled to zero New Ordinary Shares and as a result of the Share Consolidation they will cease to hold any Ordinary Shares.
3. Annual General Meeting
Set out at the end of this document is a notice convening the Annual General Meeting to be held on 11 May 2023 at 11.00 a.m. in the Malt Room at The Maltings, East Tyndall Street, Cardiff, CF24 5EA, at which the Resolutions will be proposed.
We are keen to welcome Shareholders in person to the Annual General Meeting this year and an explanation of the business to be considered at the Annual General Meeting is set out at the end of the formal notice of the Annual General Meeting which is set out at the end of this document.
Shareholders wishing to vote but who are unable to attend the Annual General Meeting in person, are urged to appoint the Chairman of the meeting as their proxy, in accordance with the relevant instructions on the form of proxy, and to submit their form of proxy so as to be received as soon as possible and by no later than 11:00 a.m. on 9 May 2023. This will ensure that your vote will be counted even if you are unable to attend in person.
4. Resolutions
A summary of the resolutions to be proposed at the Annual General Meeting is set out below. Please note that this is not the full text of the Resolutions and you should read this section in conjunction with the Resolutions contained in the formal notice at the end of this document (together with the explanatory notes set out at the end of such notice).
The following resolutions will be proposed at the Annual General Meeting:-
Resolution 1, which will be proposed as an ordinary resolution, relates to the adoption of the Company's annual accounts for the financial year ended 31 December 2022
Resolution 2, which will be proposed as an ordinary resolution, seeks Shareholder approval to appoint Gravita Audit Limited as the Company's auditor and to authorise the directors to determine their remuneration. Jeffreys Henry LLP, the Company's current auditor, has indicated that it will not seek re-appointment as the Company's auditor at the Annual General Meeting as, following a business reorganisation, the firm will provide audit services to clients from another company in its group, Gravita Audit Limited.
Resolution 3, which will be proposed as an ordinary resolution, seeks the re-appointment of Penny McCormick as a director of the Company.
Resolution 4, which will be proposed as an ordinary resolution, seeks the re-appointment of Neil Mesher as a director of the Company.
Resolution 5, which will be proposed as an ordinary resolution, seeks the re-appointment of Lyn Rees as a director of the Company.
Resolution 6, which will be proposed as an ordinary resolution, seeks Shareholder authority to approve the Share Consolidation.
Resolution 7, which will be proposed as a special resolution, seeks to alter the Articles to reflect the change to the nominal value of the Ordinary Shares following the passing of Resolution 6.
Resolution 8, which will be proposed as an ordinary resolution, seeks Shareholder authority to issue shares.
Resolution 9, which will be proposed as a special resolution, seeks Shareholder authority to dis-apply shareholder pre-emption rights on any issue of shares under the authority granted in resolution 8.
Resolution 10, which will be proposed as a special resolution, seeks authority for the Company to make market purchases of its own Ordinary Shares.
As special resolutions, each of Resolutions 7, 9 and 10 requires votes in favour representing 75 per cent. or more of the votes cast (in person or by proxy) at the Annual General Meeting in order to be passed.
5. Action to be taken by Shareholders
A form of proxy for use at the Annual General Meeting is enclosed. Whether or not you intend to be present at the Annual General Meeting, you are requested to complete, sign and return the form of proxy in accordance with the instructions thereon to the Company's Registrars at Neville House, Steelpark Road, Halesowen, West Midlands B62 8HD, so as to arrive no later than 11.00 a.m. on 9 May 2023. The return of the form of proxy will not prevent you from attending the Annual General Meeting and voting in person should you wish to do so.
If you hold your shares in uncertificated form in CREST you may appoint a proxy or proxies by utilising the CREST electronic proxy appointment service in accordance with the procedures described in the CREST Manual as set out in the Notice of Annual General Meeting at the end of this document. Proxies submitted via CREST must be received by Neville Registrars Limited (ID 7RA11) no later than 11.00 a.m. on 9 May 2023. The appointment of a proxy using the CREST electronic proxy appointment service will not preclude a Shareholder from attending and voting in person at the Annual General Meeting should they wish to do so.
6. Board Recommendations
The Directors consider that all the proposals to be considered at the Annual General Meeting are in the best interests of the Company and its shareholders as a whole and are most likely to promote the success of the Company. Accordingly, the Directors unanimously recommend that you vote in favour of the Resolutions to be proposed at the Annual General Meeting as they intend to do in respect of their own beneficial holdings currently amounting to approximately 1.9 per cent. of the issued share capital of the Company."
For further information contact:
MyHealthChecked PLC | www.myhealthchecked.com | |
Penny McCormick, Chief Executive Officer | via Walbrook PR | |
SPARK Advisory Partners Limited (NOMAD) | Tel: +44 (0)20 3368 3550 | |
Neil Baldwin | ||
Dowgate Capital Limited (Broker) | Tel: +44 (0)20 3903 7715 | |
David Poutney / Nicholas Chambers | ||
Walbrook PR Ltd (Media & IR) | Tel: +44 (0)20 7933 8780 or myhealthcheckedplc@walbrookpr.com | |
Paul McManus / Alice Woodings | Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 | |
About MyHealthChecked PLC (www.myhealthcheckedplc.com)
MyHealthChecked PLC, based in Cardiff, is an AIM-quoted pioneering UK healthcare company focused on a range of at-home healthcare and wellness tests.
MyHealthChecked is the umbrella brand of a range of at-home rapid tests, as well as DNA, RNA and blood sample collection kits which have been created to support customers on their journeys to wellness. The tests are lateral-flow self-tests, and the sample collection kits enable the collection of blood, urine, nasal or mouth swab samples that are analysed in partner laboratories for a range of biomarkers. The tests will also be made available online and will be viable for over-the -counter purchase.
The MyHealthChecked portfolio has been identified as part of a change in mindset as customers become more familiar with the concept of accessible healthcare in the growing at home testing kit market with a focus on accessibility at the right price, led by UK-based experts.